A Multi Center, Randomized, Double-blind, Parallel Design, Phase 2 Study to Evaluate the Efficacy and Safety of hzVSFv13 Compared to Standard of Care After Intravenous (IV) Administration With Add-on Standard of Care in COVID-19 Moderate to Severe Patients
Latest Information Update: 27 Aug 2021
At a glance
- Drugs Burfiralimab (Primary)
- Indications COVID-19 pneumonia
- Focus Therapeutic Use
- Sponsors ImmuneMed
- 24 Aug 2021 Status changed from recruiting to completed.
- 04 Jan 2021 Status changed from not yet recruiting to recruiting.
- 29 Dec 2020 New trial record